The Allergan BIOCELL Implants — Textured Shells Tied to Cancer and 33 Deaths

When Allergan announced a voluntary worldwide recall of its BIOCELL textured breast implants and tissue expanders on July 24, 2019 — at the request of the U.S. Food and Drug Administration — the gap between the product’s marketing and its documented harm was already a measurable oncologic toll: the FDA cited 573 unique cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) worldwide, of which 481 were attributable to Allergan devices, and 33 patient deaths, with 12 of the 13 deaths for which the implant maker was known confirmed to involve an Allergan implant. The agency’s analysis put the BIA-ALCL risk of BIOCELL macrotextured shells at roughly six times that of textured implants from other manufacturers then on the U.S. market. The implant had been sold as an ordinary reconstructive and cosmetic option; what it delivered, in a small but non-trivial fraction of recipients, was a lymphoma growing in the scar capsule around the device.

The harm was not a manufacturing defect in the conventional sense — it was the shell’s defining feature. BIOCELL was a macrotextured surface produced by a “salt-loss” process that pressed salt crystals into the silicone and dissolved them away, leaving a deeply pitted, high-surface-area shell originally marketed to anchor the implant and reduce capsular contracture. That same surface area is now the leading mechanistic suspect: it harbored more bacteria, sustained chronic biofilm and immune stimulation against the textured surface, and over years of low-grade inflammation appears to have driven T-cell transformation into ALCL in the periprosthetic capsule. The disease typically presented as a delayed seroma or mass years after implantation; caught early and treated by complete capsulectomy it was often curable, but advanced cases were lethal.

Regulators abroad moved first. France’s medicines agency, the ANSM, declined to renew the CE mark for Allergan’s macrotextured implants in December 2018 and in April 2019 became the first national regulator to ban macrotextured and polyurethane breast implants outright as a precaution. The FDA, which had publicly flagged a possible breast-implant/ALCL association as early as January 2011, did not force Allergan’s hand until July 2019 — by which point hundreds of thousands of the shells were already in patients’ bodies and would remain there, since neither the FDA nor Allergan recommended removing implants from asymptomatic women. As cumulative reporting matured, the case count climbed: by 2023 the FDA had documented on the order of 1,264 BIA-ALCL cases globally and 63 deaths, with roughly 85 percent of cases tied to Allergan textured devices. The BIOCELL recall became the modern textbook case of a device hazard that was rare, latent, and surface-intrinsic — and of a regulatory system that recognized the signal years before it acted on it.

The laparoscopic power morcellator — the Tool That Spread Hidden Uterine Cancer

When Johnson & Johnson’s Ethicon division suspended global sales of its Gynecare power morcellators in April 2014 and recalled them outright that July, the gap between the device’s promise and its harm was already written into the abdomen of the woman who had forced the action: Dr. Amy Reed, a 40-year-old Boston anesthesiologist and mother of six, had undergone a laparoscopic hysterectomy at Brigham and Women’s Hospital in October 2013 to remove presumed-benign fibroids. The morcellator — a powered tube with a rotating blade that minces tissue for extraction through keyhole incisions — shredded an undiagnosed uterine leiomyosarcoma and sprayed malignant fragments across her peritoneal cavity, advancing a contained cancer to Stage IV. The tool marketed as the enabler of fast, scarless gynecology had, in her case, converted a survivable tumor into a terminal one.

The mechanism was inherent, not incidental. No reliable preoperative test distinguishes a benign fibroid from an occult uterine sarcoma; both present as a uterine mass, and the blade cannot tell them apart. When the FDA ran the numbers in April 2014, it estimated that roughly 1 in 350 women undergoing hysterectomy or myomectomy for presumed fibroids in fact harbored an unsuspected sarcoma, and that morcellating such a tumor risked peritoneal dissemination and upstaging to FIGO Stage III or IV in approximately 25 to 65 percent of cases — sharply cutting long-term survival. The device had been in routine American use since 1993, cleared through the FDA’s 510(k) pathway as “substantially equivalent” to predicate devices, never required to show it would not seed cancer.

The reckoning came not from regulators or manufacturers but from a patient and her husband. Reed and Dr. Hooman Noorchashm, a cardiothoracic surgeon, filed her adverse-event report in December 2013 and launched a relentless public campaign. A 2017 Government Accountability Office review (GAO-17-231) found that across the device’s first two decades the FDA had received essentially no adverse-event reports linking morcellators to cancer spread — a real, recurring harm invisible to a passive surveillance system dependent on clinicians voluntarily reporting it. The FDA issued its first safety communication on April 17, 2014, J&J withdrew its market-leading devices, and on November 24, 2014, the agency mandated a boxed warning. Amy Reed died on May 24, 2017, at 44.